12:00 AM
 | 
Dec 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SF1126: Preliminary Phase I data

Preliminary data from a dose-escalation Phase I trial in 8 patients showed that 90-1,110 mg/m 2 IV SF1126 twice weekly for 4 weeks produced 1 case of stable...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >